Capivasertib Phase III trial met primary endpoints
26 October 2022 07:00 BST Capivasertib plus Faslodex significantly improved progression-free survival vs. Faslodex in CAPItello-291 Phase III trial in advanced HR-positive breast cancer Capivasertib, a potential first-in-class AKT inhibitor, combined with Faslodex could become a new option for patients in this setting regardless of biomarker status Positive high-level results from the CAPItello-291 Phase III trial showed that AstraZeneca's capivasertib in combination with Faslodex (fulvestrant) demonstrated a statistically significant and clinically meaningful improvement in